NEOGEN CORP (NEOG) Stock Fundamental Analysis
USA - NASDAQ:NEOG - US6404911066 - Common Stock
5.98 USD
-0.23 (-3.7%)
5.98 USD
0 (0%)
NEOG gets a fundamental rating of 3 out of 10. The analysis compared the fundamentals against 189 industry peers in the Health Care Equipment & Supplies industry. NEOG scores quite bad on profitability, while its financial health is fine. Not spectacular, but in line with the averages. NEOG is valued expensive and it does not seem to be growing.
1. Profitability
1.1 Basic Checks
In the past year NEOG was profitable.
In the past year NEOG had a positive cash flow from operations.
In multiple years NEOG reported negative net income over the last 5 years.
In the past 5 years NEOG always reported a positive cash flow from operatings.
1.2 Ratios
NEOG's Return On Assets of -30.88% is in line compared to the rest of the industry. NEOG outperforms 42.33% of its industry peers.
NEOG has a Return On Equity (-49.23%) which is in line with its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | -30.88% | ||
| ROE | -49.23% | ||
| ROIC | N/A |
ROA(3y)-10.81%
ROA(5y)-4.19%
ROE(3y)-17.92%
ROE(5y)-8.21%
ROIC(3y)N/A
ROIC(5y)N/A
1.3 Margins
The Gross Margin of NEOG (46.39%) is comparable to the rest of the industry.
In the last couple of years the Gross Margin of NEOG has remained more or less at the same level.
The Profit Margin and Operating Margin are not available for NEOG so they could not be analyzed.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| OM | N/A | ||
| PM (TTM) | N/A | ||
| GM | 46.39% |
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y0.72%
GM growth 5Y0.07%
2. Health
2.1 Basic Checks
NEOG does not have a ROIC to compare to the WACC, probably because it is not profitable.
Compared to 1 year ago, NEOG has about the same amount of shares outstanding.
The number of shares outstanding for NEOG has been increased compared to 5 years ago.
Compared to 1 year ago, NEOG has a worse debt to assets ratio.
2.2 Solvency
NEOG has an Altman-Z score of 0.81. This is a bad value and indicates that NEOG is not financially healthy and even has some risk of bankruptcy.
Looking at the Altman-Z score, with a value of 0.81, NEOG is in line with its industry, outperforming 48.15% of the companies in the same industry.
NEOG has a Debt/Equity ratio of 0.37. This is a healthy value indicating a solid balance between debt and equity.
NEOG has a Debt to Equity ratio (0.37) which is comparable to the rest of the industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0.37 | ||
| Debt/FCF | N/A | ||
| Altman-Z | 0.81 |
ROIC/WACCN/A
WACC7.68%
2.3 Liquidity
NEOG has a Current Ratio of 3.58. This indicates that NEOG is financially healthy and has no problem in meeting its short term obligations.
The Current ratio of NEOG (3.58) is better than 66.14% of its industry peers.
NEOG has a Quick Ratio of 2.26. This indicates that NEOG is financially healthy and has no problem in meeting its short term obligations.
Looking at the Quick ratio, with a value of 2.26, NEOG is in line with its industry, outperforming 58.20% of the companies in the same industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Current Ratio | 3.58 | ||
| Quick Ratio | 2.26 |
3. Growth
3.1 Past
The earnings per share for NEOG have decreased strongly by -25.00% in the last year.
Measured over the past years, NEOG shows a very negative growth in Earnings Per Share. The EPS has been decreasing by -10.20% on average per year.
The Revenue has decreased by -2.77% in the past year.
NEOG shows quite a strong growth in Revenue. Measured over the last years, the Revenue has been growing by 16.43% yearly.
EPS 1Y (TTM)-25%
EPS 3Y-9.82%
EPS 5Y-10.2%
EPS Q2Q%-42.86%
Revenue 1Y (TTM)-2.77%
Revenue growth 3Y19.28%
Revenue growth 5Y16.43%
Sales Q2Q%-3.58%
3.2 Future
The Earnings Per Share is expected to grow by 0.40% on average over the next years.
Based on estimates for the next years, NEOG will show a small growth in Revenue. The Revenue will grow by 0.60% on average per year.
EPS Next Y-58.27%
EPS Next 2Y-13.16%
EPS Next 3Y-14.34%
EPS Next 5Y0.4%
Revenue Next Year-7.78%
Revenue Next 2Y-3.07%
Revenue Next 3Y-1.33%
Revenue Next 5Y0.6%
3.3 Evolution
When comparing the EPS growth rate of the last years to the growth rate of the upcoming years, we see that the growth is accelerating.
When comparing the Revenue growth rate of the last years to the growth rate of the upcoming years, we see that the growth is decreasing.
4. Valuation
4.1 Price/Earnings Ratio
The Price/Earnings ratio is 19.93, which indicates a rather expensive current valuation of NEOG.
Compared to the rest of the industry, the Price/Earnings ratio of NEOG indicates a somewhat cheap valuation: NEOG is cheaper than 79.37% of the companies listed in the same industry.
NEOG's Price/Earnings ratio indicates a valuation a bit cheaper than the S&P500 average which is at 25.67.
A Price/Forward Earnings ratio of 24.03 indicates a rather expensive valuation of NEOG.
NEOG's Price/Forward Earnings ratio is a bit cheaper when compared to the industry. NEOG is cheaper than 74.60% of the companies in the same industry.
The average S&P500 Price/Forward Earnings ratio is at 31.86. NEOG is valued slightly cheaper when compared to this.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | 19.93 | ||
| Fwd PE | 24.03 |
4.2 Price Multiples
NEOG's Enterprise Value to EBITDA ratio is a bit cheaper when compared to the industry. NEOG is cheaper than 75.13% of the companies in the same industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| P/FCF | N/A | ||
| EV/EBITDA | 20.29 |
4.3 Compensation for Growth
A cheap valuation may be justified as NEOG's earnings are expected to decrease with -14.34% in the coming years.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y-13.16%
EPS Next 3Y-14.34%
5. Dividend
5.1 Amount
NEOG does not give a dividend.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A |
5.98
-0.23 (-3.7%)
Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupHealth Care Equipment & Services
GICS IndustryHealth Care Equipment & Supplies
Earnings (Last)
Earnings (Next)
Inst Owners112.45%
Inst Owner Change-0.73%
Ins Owners0.42%
Ins Owner Change83.35%
Market Cap1.30B
Revenue(TTM)886.89M
Net Income(TTM)-1.04B
Analysts76.36
Price Target7.78 (30.1%)
Short Float %10.66%
Short Ratio3.74
Dividend
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A |
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)1
Avg EPS beat(2)30.72%
Min EPS beat(2)-34.64%
Max EPS beat(2)96.08%
EPS beat(4)2
Avg EPS beat(4)15.53%
Min EPS beat(4)-34.64%
Max EPS beat(4)96.08%
EPS beat(8)2
Avg EPS beat(8)-1.35%
EPS beat(12)4
Avg EPS beat(12)52.58%
EPS beat(16)5
Avg EPS beat(16)29.73%
Revenue beat(2)1
Avg Revenue beat(2)0.03%
Min Revenue beat(2)-0.4%
Max Revenue beat(2)0.46%
Revenue beat(4)1
Avg Revenue beat(4)-0.95%
Min Revenue beat(4)-3.66%
Max Revenue beat(4)0.46%
Revenue beat(8)2
Avg Revenue beat(8)-0.99%
Revenue beat(12)3
Avg Revenue beat(12)-0.84%
Revenue beat(16)3
Avg Revenue beat(16)-1.21%
PT rev (1m)17.31%
PT rev (3m)1.67%
EPS NQ rev (1m)-8.33%
EPS NQ rev (3m)-41.07%
EPS NY rev (1m)-44.9%
EPS NY rev (3m)-62.5%
Revenue NQ rev (1m)-0.63%
Revenue NQ rev (3m)-9.21%
Revenue NY rev (1m)0.33%
Revenue NY rev (3m)-6.09%
Valuation
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | 19.93 | ||
| Fwd PE | 24.03 | ||
| P/S | 1.47 | ||
| P/FCF | N/A | ||
| P/OCF | 14.93 | ||
| P/B | 0.61 | ||
| P/tB | N/A | ||
| EV/EBITDA | 20.29 |
EPS(TTM)0.3
EY5.02%
EPS(NY)0.25
Fwd EY4.16%
FCF(TTM)-0.01
FCFYN/A
OCF(TTM)0.4
OCFY6.7%
SpS4.08
BVpS9.75
TBVpS-1.55
PEG (NY)N/A
PEG (5Y)N/A
Graham Number8.11
Profitability
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | -30.88% | ||
| ROE | -49.23% | ||
| ROCE | N/A | ||
| ROIC | N/A | ||
| ROICexc | N/A | ||
| ROICexgc | N/A | ||
| OM | N/A | ||
| PM (TTM) | N/A | ||
| GM | 46.39% | ||
| FCFM | N/A |
ROA(3y)-10.81%
ROA(5y)-4.19%
ROE(3y)-17.92%
ROE(5y)-8.21%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexgc growth 3YN/A
ROICexgc growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y0.72%
GM growth 5Y0.07%
F-Score3
Asset Turnover0.26
Health
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0.37 | ||
| Debt/FCF | N/A | ||
| Debt/EBITDA | 8.03 | ||
| Cap/Depr | 75.94% | ||
| Cap/Sales | 10.17% | ||
| Interest Coverage | N/A | ||
| Cash Conversion | 88.14% | ||
| Profit Quality | N/A | ||
| Current Ratio | 3.58 | ||
| Quick Ratio | 2.26 | ||
| Altman-Z | 0.81 |
F-Score3
WACC7.68%
ROIC/WACCN/A
Cap/Depr(3y)85.8%
Cap/Depr(5y)97.5%
Cap/Sales(3y)10.58%
Cap/Sales(5y)8.42%
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)-25%
EPS 3Y-9.82%
EPS 5Y-10.2%
EPS Q2Q%-42.86%
EPS Next Y-58.27%
EPS Next 2Y-13.16%
EPS Next 3Y-14.34%
EPS Next 5Y0.4%
Revenue 1Y (TTM)-2.77%
Revenue growth 3Y19.28%
Revenue growth 5Y16.43%
Sales Q2Q%-3.58%
Revenue Next Year-7.78%
Revenue Next 2Y-3.07%
Revenue Next 3Y-1.33%
Revenue Next 5Y0.6%
EBIT growth 1Y-147.92%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year136.85%
EBIT Next 3Y34.41%
EBIT Next 5Y19.96%
FCF growth 1Y39.48%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y11.3%
OCF growth 3Y-5.05%
OCF growth 5Y-7.47%
NEOGEN CORP / NEOG FAQ
What is the fundamental rating for NEOG stock?
ChartMill assigns a fundamental rating of 3 / 10 to NEOG.
Can you provide the valuation status for NEOGEN CORP?
ChartMill assigns a valuation rating of 3 / 10 to NEOGEN CORP (NEOG). This can be considered as Overvalued.
How profitable is NEOGEN CORP (NEOG) stock?
NEOGEN CORP (NEOG) has a profitability rating of 3 / 10.
What is the earnings growth outlook for NEOGEN CORP?
The Earnings per Share (EPS) of NEOGEN CORP (NEOG) is expected to decline by -58.27% in the next year.